OBJECTIVES: This study reports the results of an economic model predicting differences in lifetime cost of health care services consumed following heart valve surgery by prosthesis type. This model examines: Mechanical Valve (MV), Stented Tissue (ST) and the emerging Transcatheter Valve (replacement surgery only) METHODS: The economic model assumes a 55-year-old valve disease patient requiring surgery with a 25 year post-surgery life expectancy. Peer reviewed journals provided estimates of complication event rates by prosthesis type. The model estimated costs for two possible types of valve replacement procedure at year 15 for patients receiving initial ST prosthesis: 1) a second ST surgery (ST), or 2) a transcatheter valve in valve (ViV) approach. Average annual inflation rate of 3% was used. Clinical events included: initial valve surgery; thrombotic events; bleeding events; warfarin and monitoring; echo monitoring; paravalular leak; endocarditis; pacemaker insertion following valve surgery; reoperation due to structural valve deterioration; and clinical complications following transcatheter procedures. RESULTS: Cumulative costs were estimated to be $124,200 using MV during initial surgery; $183,600 using STs; and $478,048 using ViV. The MV resulted in lower expected health care costs in every year versus either ST approaches. The MV choice at the initial surgery results in a lifetime cost saving of $59,400 and $353,882 compared to using STs and ViV, respectively. The MV approach obtains the majority of its savings after year 15. CONCLUSIONS: Our model estimates changing initial prosthesis choice to the MV in the estimated 20,000 ST valve surgeries performed annually in the U.S. among patients below age 65 would result in approximately $1.2 billion lifetime reduction in direct health care expenditures over the next 25 years, The majority of savings occur when these patients would be Medicare Beneficiaries.
OBJECTIVES: Platinum chromium everolimus-eluting stents (PtCr-EES) were compared to cobalt chromium everolimus-eluting stents (CoCr-EES) in the randomized controlled PLATINUM trial. Clinical outcomes including rates of target vessel revascularization (TVR), myocardial infarction (MI), and cardiac death have been reported through 2 years (n=1507), with 3 year data to come. An economic analysis was performed to assess the cost-effectiveness of PtCr-EES versus CoCr-EES accounting for stent reimbursement practice, in which payers reimburse by procedure but hospitals bear the direct cost of stents. METHODS: A Markov model was used to compare costs from payer (Medicare) and hospital perspectives of PtCr-EES versus CoCr-EES over two years, based. The model explicitly accounted for costs (2013) of differences in index procedure and longterm cardiac events. Payer costs for the index procedure were increased only for those bailout (unplanned) stents associated with major complicating conditions (MCC; aortic dissections or extended length of stay), while hospital costs reflected all stents used (bailout or planned). Similarly, those MIs concurrent with TVR and all stent thromboses were modeled as MCCs of the TVRs, not separate events. RESULTS: PtCr-EES was cost saving versus CoCr-EES by $277/patient from a payer perspective, due to reduced costs for bailout stenting during the index procedure (3.1% vs. 4.2%) and TVR over 2 years (4.3% versus 5.4%). Probabilistic sensitivity analysis found PtCr-EES was economically dominant (more effective and less costly) in 81% of replications. From a hospital perspective, PtCr-EES saved an additional $151/patient in reduced stent acquisition costs. A detailed costing analysis would be required to determine how much of the $277/patient reduction in reimbursement reflects reduced hospital costs, and thus total societal savings. CONCLUSIONS: PtCr-EES was found to be cost saving versus CoCr-EES from both payer and hospital perspectives, primarily due to reduced TVR over 2 years. Total societal savings may be up to $428/patient.
PCV50 EVALUATING THE AVERAGE REINTERVENTIONS, REINTERVENTION COSTS AND TOTAL COSTS FOR A HEPARIN-BONDED EPTFE STENT-GRAFT IN PATIENTS WITH ATHEROSCLEROTIC DISEASE OF THE SFA
Mohr BA 1 , Martinell MJ 2 , Sheen AL 1 1 W.L. Gore & Associates, Inc., Phoenix, AZ, USA, 2 W.L. Gore & Associates, Inc., Flagstaff, AZ, USA 
OBJECTIVES:
We examined the average number of reinterventions, average reintervention costs (ARC), and the average total costs (ATC) for the latest iteration of a heparin-bonded ePTFE Stent-Graft versus a bare metal stent (BMS) in patients treated for atherosclerotic disease of the superficial femoral artery (SFA). ATC includes costs for the initial implant, reinterventions, and follow-up care. METHODS: As previously reported by Saxon (2011) and Ansel (2011) , two independent clinical studies of the Stent-Graft were recently completed. Oneyear results from the multicenter, single-arm, VIPER trial were compared to the one-year results of the BMS arm from the three-year, multicenter, randomized VIBRANT trial. The Stent-Graft used in the VIPER trial is the latest iteration of the device in use today. Patient characteristics were similar in both trials. Cost data from the Centers for Medicare and Medicaid Services was used to estimate ARC and ATC for all patients, and secondarily, for patients oversized ≤20% at the proximal edge of the Stent-Graft (instructions for use recommend 5-20% oversizing). RESULTS: The Stent-Graft group trended toward fewer reinterventions per patient than the BMS group (0.36 vs. 0.63, P=0.15), lower ARC ($3,143 vs. $4,346, P=0.38), and higher ATC ($16,482 vs. $14,987, P=0.36) through one year follow-up. Patients oversized ≤20% trended toward fewer reinterventions per patient (0.21 vs. 0.63, P=0.08), lower ARC ($1,588 vs. $4,346, P=0.05), which was statistically significant, and lower ATC ($14,524 vs. $14,987, P=0.78) versus the BMS. CONCLUSIONS: Based on the comparison of one-year follow up data, the Stent-Graft trended toward reducing reinterventions and ARC for all patients being treated for atherosclerotic SFA disease compared to BMS. When oversized ≤20% at the proximal edge, the Stent-Graft reduced ARC (statistically significant finding) and trended toward reducing reinterventions and ATC. Long-term follow up will be needed to measure the benefits beyond one year for all patients.
PCV51 ECONOMIC IMPACT OF SWITCHING FROM METOPROLOL TO NEBIVOLOL FOR HYPERTENSION TREATMENT: A RETROSPECTIVE DATABASE ANALYSIS
Chen S, Tourkodimitris S, Lukic T Forest Research Institute, Jersey City, NJ, USA OBJECTIVES: Estimate the real-world economic impact of switching from metoprolol, the most commonly prescribed β-blocker for hypertension in the US, to nebivolol, a novel well-tolerated β-blocker with high β1 selectivity and vasodilatory properties, for hypertension treatment. METHODS: Retrospective database analysis with a pre and post study design was conducted using MarketScan database (2007) (2008) (2009) (2010) (2011) . Hypertensive patients continuously treated with metoprolol for at least six months (pre-period) and then switched to nebivolol for at least six months (post-period) were identified. The first nebivolol dispensing date was defined as the index date for switching. Data were collected for the two six-month periods pre-and post-switching. Monthly health care resource utilization and health care costs pre and post switching were calculated and compared using Wilcoxon and paired t-tests. Medical costs at different years were inflated to the 2011 dollar using medical component consumer price index. RESULTS: A total of 2259 patients, with a mean age of 60, met the selection criteria. Among them, 52% were male, 37% had cardiovascular (CV) disease. After patients switched to nebivolol, there were statistically significant reductions in the number of all-cause hospitalization (p<0.01), CV related hospitalization (p<0.01), outpatient visits (p<0.01), and CV related emergency room (ER) visits (p=0.01). Monthly inpatient costs reduced $106 (p<0.01), while monthly drug cost increased $49 (p<0.01). There were reductions on costs of outpatient and ER visits, but the differences were not statistically significant. Overall health care cost reduced $63 per patient per month. Sensitivity analysis on length of medication exposure found similar results. CONCLUSIONS: This real-world study finds that patients who switched from metoprolol to nebivolol had a lower overall health care cost after switching.
PCV52 ECONOMIC BURDEN OF ACUTE CORONARY SYNDROME IN A GEOGRAPHICALLY DISTRIBUTED POPULATION FROM 2006 TO 2011 IN THE UNITED STATES
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) A 1 -A 2 9 8 A281 Cziraky MJ 1 , Luthra R 1 , Fisher MD 1 , Xu Y 2 , Wilhelm K 2 , Power TP 3 , Reddy VS 2 1 HealthCore, Inc., Wilmington, DE, USA, 2 Genentech Inc., South San Francisco, CA, USA, 3 AIM Specialty Health, Deerfield, IL, USA OBJECTIVES: To evaluate health care costs following acute coronary syndromes (ACS) in patients with/without recurrent cardiovascular events (CVEs). METHODS: Patients with ≥1 ICD-9 CM codes for acute myocardial infarction (410.xx) or unstable angina (411.1x) during ACS hospitalization were identified from the HealthCore Integrated Research Database January 1, 2006 to September 30, 2011 (index event date defined as first ACS hospitalization date). Patients with <12 months pre/post-index plan eligibility or <18 years old were excluded. Recurrent CVEs were defined as myocardial infarction, non-fatal stroke or coronary heart disease-related mortality. Total and CV-related hospitalization costs following index ACS were evaluated in patients with/without recurrent CVEs, adjusting for demographic characteristics, comorbidities, treatment utilization and index ACS characteristics. RESULTS: Of 140,903 US patients, 22.0% had ≥1 subsequent CVE during follow-up. Patients with versus without recurrent CVEs were older -and had more comorbidities. Mean (median) follow-up was 2.0 (1.6) and 1.9 (1.5) years in patients with and without recurrent CVEs, respectively. Mean (median) length of stay for index ACS hospitalization was longer in patients with versus without recurrent CVEs. Mean (median) 1-year post-index total and CV-related cost were higher in patients with versus without recurrence ($41,478 [$17,474] and $34,094 [$10,057] versus $30,608 [$17,241] and $23,613 [$10,336]; p<0.001). Inpatient hospitalization costs were the major driver of total expenditures, comprising 76% and 72% of total costs in patients with versus without recurrence, respectively. Mean 2-and 3-year post-index total and CVrelated costs were also significantly higher in patients with recurrent CVEs (2year: $27,746 and $20,572 vs. $18,707 and $12,794; 3-year: $21,880 and $15,260 vs. $14,438 and $9,049; p<0.001) . CONCLUSIONS: Following ACS hospitalization, patients with recurrent CVEs incurred higher 1-, 2-and 3-year post-index event costs compared those without recurrence, underscoring the need to focus on the prevention of subsequent adverse CVEs following ACS to improve patient outcomes and reduce total health care cost.
PCV53 CLINICAL AND ECONOMIC BURDEN OF COMPLICATIONS ASSOCIATED WITH CORONARY ARTERY BYBASS GRAFT AND/OR VALVE SURGERY
Lim S 1 , Delatore P 1 , Daskiran M 2 , Levine R 2 , Riebman J 1 1 Ethicon, Inc, Somerville, NJ, USA, 2 Johnson & Johnson, New Brunswick, NJ, USA OBJECTIVES: An increasing proportion of coronary artery bypass grafting (CABG) surgery is performed with concomitant valve repair or replacement surgery, and complications related to these procedures can have significant impact on patients and health care systems. This study quantifies the incidence and clinical and economic burden of complications associated with CABG, valve and combined (CABG and valve) surgery in the US. METHODS: Premier Perspective database was used to identify patients having CABG and/or valve surgery between Jan 2008 to Dec 2011. The study complications were postoperative infection, septicemia, postoperative stroke, postoperative adult respiratory distress syndrome, new-onset hemodialysis, reoperation, respiratory complication, cardiac complication, and hemorrhage. Both surgeries and complications were identified by ICD-9 codes. This study investigated (1) overall incidence rate of any study complication, (2) differences in length of stay (LOS), and (3) total inpatient costs for patients with and without complications during index and readmission within 30 days across three procedures. For multivariate adjustments, Gamma-distributed generalized linear model (GLM) and Poissondistributed GLM models were used. RESULTS: Of 100,601 patients who underwent CABG alone, 31,903 (31.7%) had any study complications during their index or readmitted stay. Patients with valve alone or combined surgery had higher incidence of complications: 38.2% and 47.3% (p<0.01 for both), respectively. Complications in CABG incurred additional average LOS of 4.8 days (p<0.01) and additional average hospital cost of $14,699 (p<0.01) over CABG patients not experiencing complications, while complications in valve alone and combined surgery incurred an additional 6.8 days, $23,464 and 6.7 days, $24,985 respectively. CONCLUSIONS: Results showed complications in CABG and/or valve surgery increase clinical and economic burden by 0.41 to 0.60 times in terms of additional LOS and hospital costs. The burden increases significantly when a patient has combined procedures. The results highlight the potential opportunity for cost reduction by preventing the complications associated with CABG and/or valve surgeries.
PCV54 HOW BIG IS THE DIFFERENCE BETWEEN MARGINAL COST VERSUS TOTAL COST ESTIMATES? THE CASE OF ISCHEMIC STROKE IN SOUTH CAROLINA (SC)
Simpson AN, Bonilha HS, Kazley AS, Zoller JS, Ellis C Medical University of South Carolina, Charleston, SC, USA OBJECTIVES: Cost of illness in ischemic stroke has historically been reported as direct total health care cost, not compared to an equally ill, non-stroke, control group. This methodology likely overestimates cost and may affect national burden of illness estimates and cost effectiveness comparisons. The magnitude of the over-estimation is not known. The objective of this study is to estimate the 1-year marginal cost of ischemic stroke in SC Medicare beneficiaries and examine the impact of total versus marginal cost reporting on overall US stroke cost estimates and on the distribution of expenditures of inpatient care and rehabilitation. METHODS: Cost of illness was estimated from a Medicare cost perspective for ischemic stroke in South Carolina. Stroke patients were matched 1:2 to non-stroke beneficiaries using nearest-neighbor propensity score matching. Standard Medicare analytic files for all beneficiaries in SC in 2004 and 2005 were summed for the year following their index ischemic stroke or to death. The total study sample size was 8928. RESULTS: The use of a marginal costing approach produced lower estimates than the average total costing method. The 2004 marginal costs of stroke were $26.9 million, while the average cost estimate was $81.3 million, a difference of $54.4 million. Average total cost includes expenditures for comorbid conditions which are common in patients with stroke. Cost of stroke for the US in 2012 would be overestimated by $4.89 billion if this difference is generalized to national estimates. Furthermore, the proportion of stroke costs attributable to rehabilitation services would change from 13.7% based on mean cost, to 29.3% using marginal estimates. CONCLUSIONS: Using a marginal costing approach to estimate health care costs for conditions common in patients with a high prevalence of comorbid conditions is essential for accurate estimation of burden of illness, as well as estimating in-hospital and follow-up cost distributions correctly. San. Ltd. Sti., Istanbul, Turkey, 2 Yorum Consultancy Ltd., Istanbul, Turkey, 3 Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 4 Trakya University, Edirne, Turkey, 5 Ege University Faculty of Medicine, Izmir, Turkey OBJECTIVES: To estimate the costs-of-disease and direct cost components of thromboembolic complications associated with AF and the side-effects related with anticoagulant treatment, in Turkish setting. METHODS: A panel consisting of experts on cardiology, hematology, pulmonology and neurology, held a meeting to discuss the disease management processes of stroke, SE, IC bleeding and EC bleeding. They reviewed the global and local literature and guidelines, and also they discussed the spectrum of local clinical practices that are performed frequently. All cost components, including medications, surgical treatment, hospitalization, out-patient follow-up procedures and rehabilitation services were reviewed. September 2012 local prices for medications and procedures were used as sources. Mid-2012 USD currency rate was used. RESULTS: The cost of SE was estimated as 431 USD/event (70% nonpharmacologic treatment cost). The cost of acute management of stroke was calculated as 2,517 USD, of which 76% was caused by hospital stay. The annual cost of follow-up of stroke patients was 799 USD/year. The source of almost half (48%) of the cost was non-pharmacologic treatment (namely neurologic rehabilitation). The cost of major EC bleeding was 1014 USD/event (48% hospital stay cost) and the cost of minor EC bleeding is 49 USD/event (~100% hospital stay cost). The cost of acute management of IC bleeding was calculated as 6166 USD/event (86% hospital stay cost). The annual cost of follow-up of patients with IC bleeding was 728 USD/year (52% non-pharmacologic treatment cost). CONCLUSIONS: The costs of thromboembolic complications in AF patients are quite high. The acute events of stroke or IC bleeding are quite costly, and additional costs continue to happen due to treatment of neurologic disabilities caused by the primary event. Therefore, the economic burden of these thromboembolic events might be well reduced, if the prevention of these events could be prevented in AF patients.
PCV55 THE COST-OF-DISEASE OF THROMBOEMBOLIC AND HEMORRHAGIC COMPLICATIONS ASSOCIATED WITH ATRIAL FIBRILLATION AND ITS TREATMENT IN TURKEY: AN EXPERT PANEL APPROACH FOR ESTIMATION OF COSTS

PCV56
COSTS OF ILLNESS FOR PATIENTS WITH VENOUS THROMBOEMBOLISM IN CHINA
Wu J 1 , Yang L 2 , Zhu G 3 1 Peking University, Beijing, Beijing, China, 2 Peking University, Beijing, China, 3 Bayer Healthcare Company Ltd., Beijing, Beijing, China OBJECTIVES: Venous thromboembolism (VTE), a condition that includes deep vein thrombosis (DVT) and pulmonary embolism (PE) is associated with major morbidity and mortality and causes huge economic burden. The purpose of this study was to evaluate direct and indirect costs of patients with VTE in China, producing an average cost per patient per year. METHODS: A cost-of-illness analyses was performed. The economic data was collected from an observational retrospective study. We recruited 154 patients diagnosed with VTE in Beijing, Shanghai and Guangzhou between October 2012 and December2012. Patients or their carers completed a questionnaire about resource utilization and absenteeism from work in the past year by an interview. Direct medical costs included outpatient visit, hospitalization,, ambulatory, drug, diagnostic tests, and physiotherapy costs. Indirect costs were estimated using a human capital approach. All costs referred to 2011. RESULTS: Among 154 patients, DVT accounted for 85.7%,51.95% were female and the mean age was 61.5±12.4. 96.8% patients have at least one kind of health insurance. From the societal perspective, total costs per patient over 1 year amounted to Chinese Yuan (CNY) 21484 (median: CNY14039, IQR: CNY6714-CNY32036). The direct medical costs were CNY15899 accounting for 74% of the total. The informal care costs were CNY3623 accounting for 16.9% of the total. And the indirect costs were CNY1678 accounting for 7.8%. CONCLUSIONS: The economic burden of VTE in China is considerable. The primary burden on patients was due to the direct medical costs.
